Selexis SA

107 articles about Selexis SA

• JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for Partners

  5/31/2023

  JSR Life Sciences today announced that KBI Biopharma, Inc. (KBI) and Selexis SA are consolidating as one organization under the KBI Biopharma name to accelerate innovation and growth for its global biopharma customers.

• KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO

  4/17/2023

  KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D. Mowery as Chief Executive Officer (CEO).

• Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

  9/8/2022

  Selexis SA and NexImmune Inc. announced that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients.

• KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland

  7/6/2022

  KBI Biopharma SA and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland.

• KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva, Switzerland

  6/14/2022

  KBI Biopharma SA and Selexis SA, both JSR Life Sciences companies, announced that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.

• JSR Life Sciences Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead KBI Biopharma and Selexis SA

  5/2/2022

  JSR Life Sciences, LLC announced that Mark W. Womack will serve as the Chief Executive Officer of two of its affiliate companies: KBI Biopharma, a leading global CDMO specializing in drug development and biologics manufacturing, and Selexis SA, an industry-leading cell line development provider.

• Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

  2/9/2022

  Selexis SA and Generium JSC announced that Genolar®, Generium’s biosimilar of omalizumab, is now commercially available in Russia for the treatment of persistent atopic bronchial asthma and resistant chronic idiopathic urticaria.

• Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program

  1/19/2022

  Selexis SA , a JSR Life Sciences company, and Inotrem SA , an advanced clinical-stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, have signed a service agreement to develop the cell line for Inotrem’s antibody-based candidate to address chronic inflammations.

• Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx’s Acute Myeloid Leukemia (AML) CDX Bispecific Antibody to Human Trials

  1/12/2022

  Hemogenyx Pharmaceuticals will leverage Selexis’ SUREtechnology Platform™ of protein expression technologies and modular workflows.

• Meet Selexis During Key Industry Conferences to Learn About the Latest Innovations in Cell Line Development

  11/1/2021

  Selexis SA , a JSR Life Sciences company, today announced that business and scientific leaders from the company will participate at key in-person and virtual scientific and life sciences industry partnering conferences through December 2021.

• Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

  6/29/2021

  Selexis SA and KBI Biopharma announced today that they have signed service agreements with Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies.

• Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business Officer

  6/1/2021

  Selexis Appoints Roland Hoffmann- Hecht, PhD, as Chief Business Officer Business Development Executive in Biologics Drug Development and Manufacturing Brings More than 25 Years of Biopharmaceutical Industry Experience

• Great Place to Work® Designates Selexis as One of the Best Workplaces™ Switzerland for Fourth Straight Year

  5/27/2021

  Selexis SA, a JSR Life Sciences company, announced that Great Place to Work® has designated the Company among the “Best Workplaces™ Switzerland” in 2021.

• Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

  3/23/2021

  Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service Agreements

• Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

  3/16/2021

  Pandion will leverage Selexis’ proprietary technology platform to advance an antibody targeting autoimmune and inflammatory diseases

• Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT’s Lead TNFR2 Oncology Candidate

  3/9/2021

  Selexis SA and Boston Immune Technologies and Therapeutics (BITT) have entered into a service agreement to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and infectious diseases.

• Selexis Names Biopharmaceutical Executive Dirk Lange as New Chief Executive Officer

  10/16/2020

  Selexis SA , a JSR Life Sciences Company, today announced the appointment of Dirk Lange to Chief Executive Officer (CEO). Mr. Lange succeeds the company’s founding CEO, Dr. Igor Fisch, who had led the company since he co-founded it in 2001 and is departing to pursue other opportunities. As new Selexis CEO, Mr. Lange will help advance the continued market adoption of Selexis’ cell line development technologies and oversee th

• Selexis Expands Scientific and Operational Leadership Teams with Key Promotions

  5/19/2020

  Selexis SA , a JSR Life Sciences Company, today announced key promotions across its scientific and operational leadership teams. Effective immediately, the following individuals have been promoted: Myriam Adam, PhD, to vice president, operations and intellectual property; Séverine Fagète, PhD, to vice president, cell line development services; and Valérie Le Fourn, PhD, to vice president, research. “Amid this gl

• Great Place to Work® Certifies Selexis as a 2020 Best Workplace in Switzerland for Third Year In a Row

  4/21/2020

  Selexis SA, a JSR Life Sciences Company, announced that Great Place to Work® has recognized the Company as one of the “Best Workplaces in Switzerland 2020.” Selexis joins companies of all sizes from all industries whose employees think they have an especially trustworthy, appreciative and attractive workplace culture.

• Women In Bio Names Selexis Director of Business Development and Licensing Jessica Bosc as President

  2/11/2020

  Selexis SA, a JSR Life Sciences Company, announced that Women In Bio has named Jessica Bosc, Selexis Director of Business Development and Licensing, as the organization’s President following a one-year term as President-Elect.